Psychology
Neurobiological mechanisms of ketamine's rapid antidepressant action in treatment-resistant depression
Quick fact
A single subanesthetic dose of ketamine can produce antidepressant effects within hours that last up to a week, even in patients who haven't responded to multiple other treatments. It works by blocking NMDA receptors, which triggers a quick release of glutamate and activation of AMPA receptors, leading to a burst of new synaptic connections.
Why this is interesting
Most antidepressants take weeks to work—if they work at all. But a single dose of an anesthetic can ease severe depression within hours. How can that be possible?
Read the full explanation
Understanding Neurobiological mechanisms of ketamine's rapid antidepressant action in treatment-resistant depression
Think of the brain's synapses as roadways for chemical messages. In depression, some of these roadways become weak or shut down, especially in areas that regulate mood (like the prefrontal cortex). Traditional antidepressants (SSRIs) work by slowly increasing certain signal molecules (serotonin) in the gaps between neurons, hoping to rebuild those connections over weeks. Ketamine, on the other hand, does something different. It temporarily occupies a specific 'receiving dock' (the NMDA receptor) for the brain's most common messenger, glutamate. When ketamine blocks this receptor, it triggers a rebound: a surge of glutamate that preferentially activates a different type of receptor (AMPA). This AMPA surge sends a powerful 'grow' signal inside the neurons, leading to the production of proteins that build new connections. Within hours, dendrites in key mood-regulating areas sprout new spines, and existing connections are strengthened. This rapid 'rewiring' is why relief comes so fast.
A deeper explanation
Ketamine works through a carefully choreographed cascade. At the molecular level, ketamine's blockade of NMDA receptors on GABAergic interneurons—which normally inhibit glutamate release—results in a transient disinhibition of pyramidal neurons. This leads to a burst of glutamate release. The glutamate then stimulates AMPA receptors on the same neurons, which triggers a depolarization that activates voltage-dependent calcium channels. The resulting calcium influx activates a signaling cascade involving the small GTPase Ras, leading to the phosphorylation of ERK and subsequent activation of mTORC1. mTORC1 is a master regulator of protein synthesis. It phosphorylates downstream targets like p70S6K and 4E-BP1, which in turn promote translation of synaptic proteins such as GluA1 (an AMPA receptor subunit) and PSD-95. Simultaneously, ketamine suppresses eEF2 kinase, which removes a brake on BDNF (brain-derived neurotrophic factor) translation. BDNF is a quintessential growth factor for neurons. It binds to tropomyosin receptor kinase B (TrkB) and amplifies the mTORC1 pathway. The resulting increase in synaptic density and function in brain regions associated with depression (medial prefrontal cortex, hippocampus) counteracts the synaptic loss thought to underlie the disorder. This cascade explains ketamine's rapid efficacy and provides a framework for understanding why conventional antidepressants that only target monoamines often fail in treatment-resistant cases.